16,794 reports of this reaction
5.8% of all NATALIZUMAB reports
#2 most reported adverse reaction
MULTIPLE SCLEROSIS RELAPSE is the #2 most commonly reported adverse reaction for NATALIZUMAB, manufactured by Biogen Inc.. There are 16,794 FDA adverse event reports linking NATALIZUMAB to MULTIPLE SCLEROSIS RELAPSE. This represents approximately 5.8% of all 289,050 adverse event reports for this drug.
NATALIZUMAB has an overall safety score of 75 out of 100. Patients taking NATALIZUMAB who experience multiple sclerosis relapse should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
MULTIPLE SCLEROSIS RELAPSE is moderately reported among NATALIZUMAB users, representing a notable but not dominant share of adverse events.
In addition to multiple sclerosis relapse, the following adverse reactions have been reported for NATALIZUMAB:
The following drugs have also been linked to multiple sclerosis relapse in FDA adverse event reports:
MULTIPLE SCLEROSIS RELAPSE has been reported as an adverse event in 16,794 FDA reports for NATALIZUMAB. This does not prove causation, but indicates an association observed in post-market surveillance data.
MULTIPLE SCLEROSIS RELAPSE accounts for approximately 5.8% of all adverse event reports for NATALIZUMAB, making it one of the most commonly reported side effect.
If you experience multiple sclerosis relapse while taking NATALIZUMAB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.